Comparing 2 hypotheses side-by-side
RAB29 functions as a gatekeeper—when lysosomes swell, RAB29-GTP increases, recruits LRRK2, and G2019S hyperphosphorylates RAB10 disproportionately. The amplification is RAB29-dependent. Strategic pivot: RAB29 serves as predictive biomarker rather than drug target. RAB29 knockout in G2019S patient-derived neurons would determine if amplification requires RAB29.
This hypothesis proposes that selective inhibition of CYP46A1 in specific brain regions can provide neuroprotection in neurodegenerative diseases through cholesterol retention mechanisms. While conventional approaches focus on cholesterol efflux enhancement, this strategy leverages controlled cholesterol accumulation to stabilize neuronal membranes and enhance synaptic function. The mechanism centers on maintaining optimal cholesterol levels in synaptic membranes, where moderate cholesterol enri
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
| Dimension | RAB29 Is the Critical Molecula | CYP46A1 Inhibition Therapy for |
|---|---|---|
| Mechanistic | 0.720 | 0.900 |
| Evidence | 0.700 | 0.615 |
| Novelty | 0.820 | 0.000 |
| Feasibility | 0.780 | 0.000 |
| Impact | 0.800 | 0.000 |
| Druggability | 0.520 | 0.650 |
| Safety | 0.780 | 0.600 |
| Competition | 0.720 | 0.850 |
| Data | 0.620 | 0.750 |
| Reproducible | 0.680 | 0.700 |
| KG Connect | 0.500 | 0.750 |
No evidence citations yet
No evidence citations yet
4 rounds · quality: 0.80
# Therapeutic/Mechanistic Hypotheses Addressing LRRK2 Signal Amplification vs. Baseline Elevation --- ## Hypothesis 1: G2019S Acts as a Lysosomal Volume-Sensing Amplifier via Enhanced RAB29-Dependen...
# Critical Evaluation of LRRK2 Hypotheses ## Overview The core question—whether G2019S increases signal amplification during lysosomal swelling versus merely elevating the baseline activity floor—re...
# Feasibility Assessment: LRRK2 G2019S Signal Amplification vs. Baseline Elevation Hypotheses ## Executive Summary The core mechanistic question—whether LRRK2 G2019S drives pathology through amplifi...
```json { "ranked_hypotheses": [ { "title": "Therapeutic Window Exists Because Amplified Signals (Not Baseline) Drive Pathogenesis (H3)", "description": "G2019S basal RAB10 phosphory...
5 rounds · quality: 0.93
Based on my research, here are 7 novel therapeutic hypotheses targeting lipid raft-mediated neurodegeneration: ## 1. Selective Acid Sphingomyelinase Modulation Therapy **Description:** Partial inhibi...
Based on the provided literature on lipid raft composition changes in neurodegeneration, here are 7 novel therapeutic hypotheses: ## Hypothesis 1: Cholesterol-Sphingolipid Ratio Modulators as Synapti...
Based on my research, here are 7 novel therapeutic hypotheses targeting lipid raft-mediated neurodegeneration: ## 1. Selective Acid Sphingomyelinase Modulation Therapy **Description:** Partial inhibi...
Maximum tool use rounds reached...
Curated mechanism pathway diagrams from expert analysis
graph TD
A["CYP46A1 Gene Therapy
Vector Delivery"] -->|"increases"| B["CYP46A1 Enzyme
Expression"]
B -->|"converts"| C["Cholesterol to
24S-Hydroxycholesterol"]
C -->|"crosses"| D["Blood-Brain Barrier
Efflux"]
D -->|"reduces"| E["Brain Cholesterol
Levels"]
E -->|"disrupts"| F["Lipid Raft
Microdomains"]
F -->|"decreases"| G["gamma-Secretase
Activity"]
G -->|"reduces"| H["Amyloid-beta
Production"]
E -->|"modulates"| I["Cholesterol-dependent
APP Processing"]
I -->|"shifts to"| J["Alpha-secretase
Pathway"]
J -->|"increases"| K["sAPP-alpha
Neuroprotective Fragment"]
H -->|"decreases"| L["Amyloid Plaque
Formation"]
C -->|"activates"| M["LXR Nuclear
Receptors"]
M -->|"upregulates"| N["ABCA1 and APOEpsilon
Expression"]
N -->|"enhances"| O["Cholesterol and
Amyloid Clearance"]
L -->|"reduces"| P["Neuroinflammation
and Tau Pathology"]
K -->|"promotes"| Q["Synaptic Plasticity
and Neuronal Health"]
O -->|"improves"| Q
P -->|"prevents"| R["Cognitive Decline
and Neurodegeneration"]
Q -->|"leads to"| R
classDef normal fill:#4fc3f7,stroke:#2196f3
classDef therapeutic fill:#81c784,stroke:#4caf50
classDef pathology fill:#ef5350,stroke:#f44336
classDef outcome fill:#ffd54f,stroke:#ff9800
classDef molecular fill:#ce93d8,stroke:#9c27b0
class A therapeutic
class B,C,D,M,N molecular
class E,F,G,I,J normal
class H,L,P pathology
class K,O,Q,R outcome